60 Degrees Pharmaceuticals plans to unblind its randomized clinical study of tafenoquine in patients hospitalized with severe babesiosis and report primary and secondary endpoint results in January 2027. The Data Safety Monitoring Board recommended concluding enrollment at the current 30 subjects rather than adding three more, avoiding a potential delay until fall 2027. No safety signals were identified during the interim analysis. The company also intends to request a pre-sNDA meeting with the FDA in January 2027 to discuss regulatory pathways for treating babesiosis. 60 Degrees Pharmaceuticals develops and commercializes new medicines for vector-borne disease.
